ECSP22010121A - Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos - Google Patents

Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos

Info

Publication number
ECSP22010121A
ECSP22010121A ECSENADI202210121A ECDI202210121A ECSP22010121A EC SP22010121 A ECSP22010121 A EC SP22010121A EC SENADI202210121 A ECSENADI202210121 A EC SENADI202210121A EC DI202210121 A ECDI202210121 A EC DI202210121A EC SP22010121 A ECSP22010121 A EC SP22010121A
Authority
EC
Ecuador
Prior art keywords
microtubule
therapeutics
targeting agents
peptide conjugates
conjugates
Prior art date
Application number
ECSENADI202210121A
Other languages
English (en)
Inventor
Daniel Richard Marshall
Robert John Maguire
Robert A Volkmann
Johanna Marie Csengery
Original Assignee
Cybrexa 3 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 3 Inc filed Critical Cybrexa 3 Inc
Publication of ECSP22010121A publication Critical patent/ECSP22010121A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a conjugados peptídicos de agentes dirigidos a microtúbulos tales como derivados de maitansinoide que son útiles para el tratamiento de enfermedades tal como cáncer.
ECSENADI202210121A 2019-07-10 2022-02-09 Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos ECSP22010121A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962872638P 2019-07-10 2019-07-10
US202063041324P 2020-06-19 2020-06-19

Publications (1)

Publication Number Publication Date
ECSP22010121A true ECSP22010121A (es) 2022-05-31

Family

ID=71944331

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202210121A ECSP22010121A (es) 2019-07-10 2022-02-09 Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos

Country Status (17)

Country Link
US (2) US11555019B2 (es)
EP (1) EP3996749A1 (es)
JP (1) JP2022541747A (es)
KR (1) KR20220051332A (es)
CN (1) CN114302744A (es)
AU (1) AU2020311925A1 (es)
BR (1) BR112022000297A2 (es)
CA (1) CA3146385A1 (es)
CL (1) CL2022000043A1 (es)
CO (1) CO2022001315A2 (es)
CR (1) CR20220057A (es)
EC (1) ECSP22010121A (es)
IL (1) IL289659A (es)
MX (1) MX2022000450A (es)
PE (1) PE20220485A1 (es)
TW (1) TW202116356A (es)
WO (1) WO2021007402A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
MX2023008146A (es) 2021-01-08 2023-07-24 Cybrexa 2 Inc Proceso para preparar un resto enlazador de conjugados.
WO2023091957A1 (en) * 2021-11-17 2023-05-25 Cybrexa 4, Inc. Peptide conjugates of peptidic tubulin inhibitors as therapeutics

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
NZ313713A (en) 1995-08-02 2001-03-30 Univ Newcastle Ventures Ltd Benzimidazole-4-carboxamide derivatives useful as poly(ADP-ribose)polymerase or PARP enzyme inhibitors
DK0897924T3 (da) 1996-04-26 2001-11-19 Daiichi Seiyaku Co Fremgangsmåde til fremstilling af tetrahydroindoliziner
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
IN189180B (es) 1997-07-09 2003-01-04 Chong Kun Dang Corp
WO1999061061A1 (fr) 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Composites medicamenteux
EP1155702A4 (en) 1998-10-30 2004-12-15 Daiichi Seiyaku Co DDS CONNECTIONS AND TEST METHODS
HUP0200312A3 (en) 1998-11-03 2002-12-28 Basf Ag Substituted 2-phenylbenzimidazoles, pharmaceutical compositions containing them, the production thereof and their use
OA11749A (en) 1999-01-11 2005-07-19 Agouron Pharma Tricyclic inhibitors of poly(adp-ribose)polymerases.
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6699876B2 (en) 1999-11-18 2004-03-02 Les Laboratoires Servier Camptothecin analogue compounds
AU3071801A (en) 1999-12-13 2001-06-18 Eli Lilly And Company Pseudomycin phosphate prodrugs
KR20030023697A (ko) 2000-07-13 2003-03-19 다이이찌 세이야꾸 가부시기가이샤 Ｄｄｓ 화합물을 함유하는 의약 조성물
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
ES2339934T3 (es) 2002-03-01 2010-05-27 The Administrators Of The Tulane Educational Fund Conjugados de agentes citotoxicos y peptidos biologicamente activos.
WO2003080047A1 (en) 2002-03-20 2003-10-02 Bristol-Myers Squibb Company Phosphate prodrugs of fluorooxindoles
AU2003229953A1 (en) 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2004087713A1 (en) 2003-03-31 2004-10-14 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
CA2930485C (en) 2003-05-14 2018-04-10 Immunogen, Inc. Maytansinoid-antibody conjugate compositions
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CR20170291A (es) 2003-05-20 2017-07-27 Immunogen Inc Agentes citotoxicos mejorados que comprenden nuevos maitansinóides
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
KR101138471B1 (ko) 2003-07-25 2012-04-25 화이자 인코포레이티드 트리시클로 ｐａｒｐ 저해제
CA2547077C (en) 2003-12-01 2015-11-03 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
KR20090130156A (ko) 2004-09-22 2009-12-17 화이자 인코포레이티드 폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는 치료 배합물
AU2005286187B2 (en) 2004-09-22 2009-06-18 Cancer Research Technology Ltd. Method of preparing poly(ADP-ribose) polymerases inhibitors
MX2007002461A (es) 2004-09-22 2008-03-13 Pfizer Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-{4-[metilamino)metil]fenil}-1, 3, 4, 5-tetrahidro-6h-azepino [5, 4, 3-cd]indol-6-ona.
MX2007007011A (es) 2004-12-09 2007-09-21 Johnson & Johnson Inmunoconjugados anti-integrina, metodos y usos.
WO2006078816A2 (en) 2005-01-18 2006-07-27 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
AU2006213662B2 (en) 2005-02-11 2010-08-05 Immunogen, Inc. Process for preparing stable drug conjugates
EP1868649A4 (en) 2005-04-15 2011-06-29 Immunogen Inc ELIMINATION OF A POPULATION OF HETEROGENEOUS OR MIXED CELLS IN TUMORS
NZ609752A (en) 2005-08-24 2014-08-29 Immunogen Inc Process for preparing maytansinoid antibody conjugates
EP1957477B1 (en) 2005-09-29 2011-12-07 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
JP5117390B2 (ja) 2005-11-08 2013-01-16 イミュノジェン・インコーポレーテッド メイタンシノールの調製法
CA2635691C (en) 2006-01-17 2013-10-29 Abbott Laboratories Combination therapy with parp inhibitors
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
DK2805945T3 (da) 2007-01-10 2019-07-15 Msd Italia Srl Amid-substituerede indazoler som poly(adp-ribose)polymerase- (parp) hæmmere
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
JP5690589B2 (ja) 2007-06-25 2015-03-25 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 親水性スペーサーリンカーを含有する結合体
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
AU2008289108C1 (en) 2007-08-17 2024-05-23 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
SI2437790T1 (sl) 2009-06-03 2019-07-31 Immunogen, Inc. Konjugacijske metode
US9353140B2 (en) 2009-11-25 2016-05-31 Academia Sinica BQC-G, a tumor-selective anti-cancer prodrug
WO2011098971A1 (en) 2010-02-12 2011-08-18 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
CA2790577A1 (en) 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
PE20130151A1 (es) 2010-03-31 2013-02-21 Gilead Pharmasset Llc Sintesis estereoselectiva de activos que contienen fosforo
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
CA2805387C (en) 2010-07-13 2021-10-26 Rhode Island Board Of Governors For Higher Education Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
US8846081B2 (en) 2010-08-13 2014-09-30 Rhode Island Board Of Governors For Higher Education Liposome compositions and methods of use thereof
CN106349254A (zh) 2010-11-03 2017-01-25 伊缪诺金公司 包含新型安丝菌素衍生物的细胞毒性剂
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
MX369659B (es) 2011-03-29 2019-11-15 Immunogen Inc Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa.
ES2556584T3 (es) 2011-10-14 2016-01-19 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
PT2907824T (pt) 2012-10-11 2018-06-07 Daiichi Sankyo Co Ltd Conjugado de anticorpo-fármaco
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
WO2014066002A1 (en) 2012-10-23 2014-05-01 The Johns Hopkins University Novel self-assembling drug amphiphiles and methods for synthesis and use
WO2014093343A2 (en) 2012-12-10 2014-06-19 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
IL290330B2 (en) 2013-12-19 2023-09-01 Seagen Inc Methylene carbamate binders for use with drug-targeting conjugates
EP3094752A4 (en) 2014-01-16 2017-08-16 Clovis Oncology, Inc. Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
DK3129063T3 (da) 2014-04-10 2021-04-06 Daiichi Sankyo Co Ltd Anti-her3-antistof-lægemiddelkonjugat
US9987285B2 (en) 2014-08-22 2018-06-05 Clovis Oncology, Inc. High dosage strength tablets of rucaparib
CA2944085C (en) 2014-09-16 2018-04-10 Ease Charm Limited Anti-egfr antibody and uses of same
KR20170088905A (ko) 2014-11-19 2017-08-02 이뮤노젠 아이엔씨 세포 결합 작용제-세포독성 작용제 접합체를 제조하기 위한 공정
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
SI3380486T1 (sl) 2015-11-24 2020-07-31 Theravance Biopharma R&D Ip, Llc Predzdravila spojine zaviralca jak za zdravljenje gastrointestinalne vnetne bolezni
KR102498258B1 (ko) 2016-01-20 2023-02-10 삼성디스플레이 주식회사 표시 장치
US20170267727A1 (en) 2016-03-04 2017-09-21 Lehigh University Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
WO2017156191A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
US20200078468A1 (en) 2016-04-13 2020-03-12 Tarveda Therapeutics, Inc. Neurotensin receptor binding conjugates and formulations thereof
GB201608885D0 (en) 2016-05-20 2016-07-06 Univ Birmingham Treatment
WO2017210608A1 (en) 2016-06-02 2017-12-07 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
WO2018023098A1 (en) * 2016-07-29 2018-02-01 Memorial Sloan Kettering Cancer Center Radiolabeled ligands for targeted pet/spect imaging and methods of their use
RU2770197C2 (ru) 2016-08-16 2022-04-14 Нэшнл Инститьют Оф Эдванст Индастриал Сайенс Энд Текнолоджи Пептид злокачественной опухоли, являющийся мишенью
WO2018057912A1 (en) * 2016-09-22 2018-03-29 Rhode Island Council On Postsecondary Education FLUORESCENT COMPOUND COMPRISING A FLUOROPHORE CONJUGATED TO A pH -TRIGGERED POLYPEPTIDE
WO2018227132A1 (en) 2017-06-09 2018-12-13 Rhode Island Council On Postsecondary Education Linked and other ph-triggered compounds
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
PE20211305A1 (es) 2018-01-05 2021-07-20 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas
US20200360545A1 (en) 2018-01-12 2020-11-19 Prolynx Llc Protocol for minimizing toxicity of combination dosages and imaging agent for verification
US20210221910A1 (en) 2018-05-18 2021-07-22 Glycotope Gmbh Anti-muc1 antibody
TW202015740A (zh) 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
CN109232719B (zh) 2018-09-21 2021-06-29 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
US20200237926A1 (en) 2019-01-28 2020-07-30 Rhode Island Council On Postsecondary Education pHLIP® targeted delivery of potent cytotoxic compounds
KR102498681B1 (ko) 2019-03-29 2023-02-09 메디뮨 리미티드 화합물 및 이의 접합체
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics

Also Published As

Publication number Publication date
CR20220057A (es) 2022-07-19
MX2022000450A (es) 2022-04-25
IL289659A (en) 2022-03-01
BR112022000297A2 (pt) 2022-03-15
US20210009536A1 (en) 2021-01-14
TW202116356A (zh) 2021-05-01
CA3146385A1 (en) 2021-01-14
EP3996749A1 (en) 2022-05-18
WO2021007402A1 (en) 2021-01-14
KR20220051332A (ko) 2022-04-26
CN114302744A (zh) 2022-04-08
JP2022541747A (ja) 2022-09-27
US20240067616A1 (en) 2024-02-29
PE20220485A1 (es) 2022-04-04
CO2022001315A2 (es) 2022-05-10
US11555019B2 (en) 2023-01-17
AU2020311925A1 (en) 2022-02-03
CL2022000043A1 (es) 2022-08-19

Similar Documents

Publication Publication Date Title
ECSP22010228A (es) Conjugados peptídicos de citotoxinas como terapéuticos
ECSP22010121A (es) Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
CO2020009091A2 (es) Exosomas para inmunooncología y terapia antiinflamatoria
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
CO2022000040A2 (es) Vesículas extracelulares microbianas procesadas
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CO2022004694A2 (es) Heterociclos bicíclicos como inhibidores de fgfr
MX2017006382A (es) Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer.
UY36075A (es) Derivados de tubulisina
ECSP20061378A (es) COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma
AR104987A1 (es) Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
SV2019005822A (es) Metodos para tratar el cáncer de próstata
CO2020000227A2 (es) Moduladores de nlrp3
CO2022001083A2 (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
MX2020003862A (es) Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma).
ECSP20082988A (es) Agonistas de tlr7
AU2018275686A1 (en) Precipitation resistant small molecule drug formulations
CL2018002368A1 (es) Formulaciones de oritavancina
CL2018000726A1 (es) Tratamiento con conjugado syd985 de pacientes con cáncer resistente al tratamiento con t-dm1
BR112022022590A2 (pt) Formulações farmacêuticas de acetato de abiraterona e niraparibe
AR120058A1 (es) Vesículas extracelulares microbianas procesadas
CL2019000214A1 (es) Métodos para tratar el cáncer de próstata.